argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
583.51
+11.51 (2.01%)
At close: Aug 25, 2025
2.01%
Market Cap31.83B
Revenue (ttm)2.28B
Net Income (ttm)934.56M
Shares Outn/a
EPS (ttm)13.68
PE Ratio34.06
Forward PE30.25
Dividendn/a
Ex-Dividend Daten/a
Volume15,997
Average Volume21,008
Open571.60
Previous Close572.00
Day's Range571.60 - 599.80
52-Week Range456.80 - 656.80
Beta-0.01
RSI65.28
Earnings DateJul 31, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.